ClinicalTrials.gg
CompletedNCT06828692Updated Nov 2, 2026

Implementation of Machine Learning and Hemodynamic Profiles Based Clinical Decision Support Systems for Personalized Guideline Accordant Antihypertensive Regimens in Primary Care: a Pragmatic Cluster Randomized Controlled Trial

An interventional study of Group A (clinical guideline+machine learning) and Group B (clinical guideline+impedance cardiograph+machine learning) in Hypertension, sponsored by China National Center for Cardiovascular Diseases. Completed at 1 site in China. Open to participants aged 35 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,946
Allocation
Randomized
Ages
35 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Hypertension by China National Center for Cardiovascular Diseases — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · China National Center for Cardiovascular Diseases.

Enrollment
5th of 16
1,946 · median 480
Started
2025
with 2 others
No phase
13 of 17
6 open now
Registered
12th of 17
by date

Among the 17 studies in Hypertension by China National Center for Cardiovascular Diseases, this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, and was the 12th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 17 studies in Hypertension by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 35 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hypertension by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

This trial is a prospective, multicenter, single-blind, three-arm parallel-group, cluster randomized controlled trial assessing the effectiveness and safety of two types of CDSS in primary care settings in China. Primary care sites are randomized to one of the intervention arms or the control arm (1:1:1 ratio) using computer-generated random numbers stratified by region and administrative categories of the primary healthcare institutions (including community health centers, community health stations, and township health centers). A total of 51 primary care sites are randomized to three groups, with 17 sites assigned to group A (use a CDSS based on clinical guidelines and machine learning), 17 sites to group B (use a CDSS based on guidelines, hemodynamic parameters and ML), and the remaining 17 sites to the control group.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension
  • CDSS
  • cluster randomized controlled trial
04

Who can participate

Ages eligible
35 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 35 ≤ Age \< 80 years.
  2. Regularly attend the clinic for hypertension treatment during the study period, without plans of traveling during the study period.
  3. Diagnosed with hypertension, with SBP ≥140mmHg at screening.
  4. Currently taking 0 or 2 classes of antihypertensive medications (A/C/D), with or without concurrent use of class B.
  5. Willing to participate in the trial and capable of providing written .

Exclusion criteria

Exclusion Criteria:

  1. Physician-diagnosed or suspected secondary hypertension (e.g., hypertension caused by renal disease, renal artery stenosis, aortic stenosis, primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid dysfunction, intracranial disease, drug-induced, or rare monogenic genetic disease).
  2. SBP ≥180mmHg and/or DBP ≥110mmHg at the screening visit.
  3. Suspected or diagnosed white coat hypertension.
  4. History of coronary heart disease.
  5. History of heart failure.
  6. Intolerance to 2 or more classes of A, C,D antihypertensive medications.
  7. Currently taking antihypertensive medications other than class A,B,C and D.
  8. Diagnosed chronic kidney disease, estimating (eGFR)\< 60 ml/min·1.73m2, or receiving dialysis.
  9. Serious medical conditions (e.g., malignant cancer and hepatic dysfunction)
  10. Currently in an acute episode of disease (e.g, new-onset cardiovascular and cerebrovascular disease occurred within 3 months).
  11. Cognitive or communicative disorders.
  12. Currently pregnant or breastfeeding or planning a pregnant or breastfeeding during the study.
  13. Reluctant to take antihypertensive medications or have poor compliance with previous treatment.
  14. Participating in other clinical trials.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,946 participants (actual)

Study arms

  • Experimental
    Group A (CG+ML)

    Combination Product: Group A (clinical guideline+machine learning)

  • Experimental
    Group B (CG+ICG+ML)

    Combination Product: Group B (clinical guideline+impedance cardiograph+machine learning)

  • Other
    Group C (UC)

    Other: Group C (usual care)

Interventions

  • Combination productGroup A (clinical guideline+machine learning)

    Group A (CG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG) and machine learning (ML) approach.

  • Combination productGroup B (clinical guideline+impedance cardiograph+machine learning)

    Group B (CG+ICG+ML): A Clinical Decision Support System (CDSS) with the algorithm that incorporates clinical guideline (CG), hemodynamic parameters measured by impedance cardiograph (ICG), and machine learning (ML) approach.

  • OtherGroup C (usual care)

    Control group, the physicians manage the hypertensive patients according to their knowledge and experiences.

06

What researchers measure

Primary outcomes

  1. hierarchical composite outcome

    The primary outcome of the trial is a hierarchical composite outcome, evaluated using the Win-ratio method in the following order: 1. Office blood pressure control (\<130/80 mmHg) at 12 weeks. 2. Time to first blood pressure blood pressure control (\<130/80 mmHg) during study period. 3. The composite index of the number and dosage of antihypertensive drugs.

    Time frame: Baseline; 12 weeks.

Secondary outcomes

  1. Individual component of the three-tier hierarchical composite primary outcome at 12 weeks.

    Time frame: Baseline; 12 weeks.

  2. Changes in office systolic and diastolic BP from baseline to 4 weeks and 12 weeks.

    Time frame: Baseline; 4 weeks, 12 weeks.

  3. Average 24-hour ambulatory systolic and diastolic blood pressure, along with blood pressure control rate at 12 weeks.

    Time frame: 12 weeks.

  4. Changes in hemodynamic parameters from baseline to 12 weeks measured by ICG.

    Including dynamic parameters (heart rate and cardiac index), resistance parameters (arterial stiffness index and systemic vascular resistance index), and volume parameters (thoracic blood volume saturation)

    Time frame: Baseline; 12 weeks.

  5. Differences in the three-tier hierarchical composite primary outcome and each component between the two intervention groups at 12 weeks.

    Time frame: Baseline; 12 weeks.

Other outcomes

  1. safety outcome

    Safety outcomes include serious adverse events, non-serious adverse events, such as symptomatic hypotension or SBP \<90 mmHg, injury falls, syncope, and bradycardia (heart rate \<50 beats/minute) during study periods.

    Time frame: Baseline; 12 weeks.

07

Study locations

1 site
  • Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences
    Shenzhen, Shenzhen, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Mar 2026, 9 months.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 9 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Feb 2026 → Mar 2026 and completion May 2026 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 14, 2025
StartActual
May 26, 2025
Primary completionActual
Mar 9, 2026was Feb 2026
CompletionActual
Mar 9, 2026was May 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 2, 2026
Primary completion
Feb 28, 2026→Mar 9, 2026 (actual)
Nov 2, 2026
Study completion
May 31, 2026→Mar 9, 2026 (actual)
Nov 2, 2026
Enrollment
2160 (estimated)→1946 (actual)
Nov 2, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time framehierarchical composite outcomeBaseline; 3 months → Baseline; 12 weeks.
  • Descriptionhierarchical composite outcome: how it is measured was reworded
Nov 2, 2026
Secondary outcomes
5 edited, 1 time frame changed
What changed in the outcomes
  • EditedSeparate evaluation of eachIndividual component of the three-tier hierarchical composite primary outcome at 3 months12 weeks.Time frame: Baseline; 3 months → Baseline; 12 weeks.
  • EditedChanges in office systolic and diastolic blood pressureBP from baseline to 1 month4 weeks and 3 months12 weeks.Time frame: Baseline; 1 month; 3 months → Baseline; 4 weeks, 12 weeks.
  • EditedAverage 24-hour ambulatory systolic and diastolic blood pressure, along with blood pressure control rate at 3 months12 weeks.Time frame: 3 months → 12 weeks.
  • EditedChanges in hemodynamic parameters measured by ICG from baseline to 3 months12 weeks measured by ICG.Time frame: Baseline; 3 months → Baseline; 12 weeks.
  • EditedDifferences in the three-tier hierarchical composite primary outcomesoutcome and each component ofbetween the three-tier hierarchical composite primary outcome amongtwo intervention groups at 3 months12 weeks.Time frame: Baseline; 3 months → Baseline; 12 weeks.
  • Time frameother outcomesafety outcomeBaseline; 3 months → Baseline; 12 weeks.
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Recruiting→Completed
    Primary completion Feb 28, 2026→Mar 9, 2026 (now actual)
    Study completion May 31, 2026→Mar 9, 2026 (now actual)
    Enrollment 2160 (estimated)→1946 (actual)
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time framehierarchical composite outcomeBaseline; 3 months → Baseline; 12 weeks.
    • Descriptionhierarchical composite outcome: how it is measured was reworded
    Secondary outcomes 5 edited, 1 time frame changed
    What changed in the outcomes
    • EditedSeparate evaluation of eachIndividual component of the three-tier hierarchical composite primary outcome at 3 months12 weeks.Time frame: Baseline; 3 months → Baseline; 12 weeks.
    • EditedChanges in office systolic and diastolic blood pressureBP from baseline to 1 month4 weeks and 3 months12 weeks.Time frame: Baseline; 1 month; 3 months → Baseline; 4 weeks, 12 weeks.
    • EditedAverage 24-hour ambulatory systolic and diastolic blood pressure, along with blood pressure control rate at 3 months12 weeks.Time frame: 3 months → 12 weeks.
    • EditedChanges in hemodynamic parameters measured by ICG from baseline to 3 months12 weeks measured by ICG.Time frame: Baseline; 3 months → Baseline; 12 weeks.
    • EditedDifferences in the three-tier hierarchical composite primary outcomesoutcome and each component ofbetween the three-tier hierarchical composite primary outcome amongtwo intervention groups at 3 months12 weeks.Time frame: Baseline; 3 months → Baseline; 12 weeks.
    • Time frameother outcomesafety outcomeBaseline; 3 months → Baseline; 12 weeks.
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06828692
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
May 26, 2025
Primary completion
Mar 9, 2026
Completion
Mar 9, 2026
Last update
Nov 2, 2026

Study contacts

Xin Zheng
principal investigator · Fuwai Hospital, China Academy of Medical Sciences, National Center for Cardiovascular Diseases

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion